This study is being done in small cell lung cancer, a fast-growing type of lung cancer that has already spread widely. The purpose of the study is to compare a new treatment, obrixtamig (also called BI 764532), given by vein, with the current treatment used first, which includes atezolizumab, carboplatin, and etoposide. Atezolizumab is a medicine that helps the body’s immune system attack cancer cells, carboplatin and etoposide are chemotherapy medicines, and obrixtamig is a new study medicine designed to help immune cells find and attack cancer cells.
In the study, people are randomly assigned to receive either the new treatment combination or the standard treatment combination. The medicines are given as intravenous infusion, which means they are delivered slowly through a vein. Treatment is given in cycles over time, with regular visits for infusions and checks by the study team. The study will look at how long people live and will also follow symptoms and side effects, including breathing problems, chest pain, cough, and treatment-related reactions such as CRS and ICANS. CRS, or cytokine release syndrome, is a strong immune reaction that can cause fever and other symptoms. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a brain and nerve problem that can affect thinking, speech, or alertness.
Austria 
Belgium 
Bulgaria 
Czechia 
Estonia 
Finland 
France 
Germany 
Greece 
Hungary 
Ireland 
Italy 
Latvia 
Norway 
Poland 
Portugal 
Romania 
Spain 
Sweden 
The Netherlands